 | • レポートコード：MRC2Q12-18994 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| コロナ禍により、ジフテリア・破傷風・百日咳混合ワクチンの世界市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にジフテリア・破傷風・百日咳混合ワクチンのグローバル市場のxxx％を占める「不活性化ワクチン」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「12ヶ月以下」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 ジフテリア・破傷風・百日咳混合ワクチンの中国市場規模は2021年にUS$xxxと分析されており、アメリカとヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。アメリカの割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパのジフテリア・破傷風・百日咳混合ワクチン市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 ジフテリア・破傷風・百日咳混合ワクチンのグローバル主要プレイヤーには、Sanofi Pasteur、GSK、Mitsubishi Tanabe Pharma、KM Biologics、Wuhan Institute of Biological Products、Walvax Biotechnology、Chengdu Institute of Biological Products、Minhai Biotechnologyなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 ジフテリア・破傷風・百日咳混合ワクチン市場は、種類と用途によって区分されます。世界のジフテリア・破傷風・百日咳混合ワクチン市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 不活性化ワクチン、その他 【用途別セグメント】 12ヶ月以下、12ヶ月以上 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - ジフテリア・破傷風・百日咳混合ワクチン製品概要 - 種類別市場（不活性化ワクチン、その他） - 用途別市場（12ヶ月以下、12ヶ月以上） - 調査の目的 ・エグゼクティブサマリー - 世界のジフテリア・破傷風・百日咳混合ワクチン販売量予測2017-2028 - 世界のジフテリア・破傷風・百日咳混合ワクチン売上予測2017-2028 - ジフテリア・破傷風・百日咳混合ワクチンの地域別販売量 - ジフテリア・破傷風・百日咳混合ワクチンの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別ジフテリア・破傷風・百日咳混合ワクチン販売量 - 主要メーカー別ジフテリア・破傷風・百日咳混合ワクチン売上 - 主要メーカー別ジフテリア・破傷風・百日咳混合ワクチン価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（不活性化ワクチン、その他） - ジフテリア・破傷風・百日咳混合ワクチンの種類別販売量 - ジフテリア・破傷風・百日咳混合ワクチンの種類別売上 - ジフテリア・破傷風・百日咳混合ワクチンの種類別価格 ・用途別市場規模（12ヶ月以下、12ヶ月以上） - ジフテリア・破傷風・百日咳混合ワクチンの用途別販売量 - ジフテリア・破傷風・百日咳混合ワクチンの用途別売上 - ジフテリア・破傷風・百日咳混合ワクチンの用途別価格 ・北米市場 - 北米のジフテリア・破傷風・百日咳混合ワクチン市場規模（種類別、用途別） - 主要国別のジフテリア・破傷風・百日咳混合ワクチン市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのジフテリア・破傷風・百日咳混合ワクチン市場規模（種類別、用途別） - 主要国別のジフテリア・破傷風・百日咳混合ワクチン市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のジフテリア・破傷風・百日咳混合ワクチン市場規模（種類別、用途別） - 主要国別のジフテリア・破傷風・百日咳混合ワクチン市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のジフテリア・破傷風・百日咳混合ワクチン市場規模（種類別、用途別） - 主要国別のジフテリア・破傷風・百日咳混合ワクチン市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのジフテリア・破傷風・百日咳混合ワクチン市場規模（種類別、用途別） - 主要国別のジフテリア・破傷風・百日咳混合ワクチン市場規模（トルコ、サウジアラビア） ・企業情報 Sanofi Pasteur、GSK、Mitsubishi Tanabe Pharma、KM Biologics、Wuhan Institute of Biological Products、Walvax Biotechnology、Chengdu Institute of Biological Products、Minhai Biotechnology ・産業チェーン及び販売チャネル分析 - ジフテリア・破傷風・百日咳混合ワクチンの産業チェーン分析 - ジフテリア・破傷風・百日咳混合ワクチンの原材料 - ジフテリア・破傷風・百日咳混合ワクチンの生産プロセス - ジフテリア・破傷風・百日咳混合ワクチンの販売及びマーケティング - ジフテリア・破傷風・百日咳混合ワクチンの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - ジフテリア・破傷風・百日咳混合ワクチンの産業動向 - ジフテリア・破傷風・百日咳混合ワクチンのマーケットドライバー - ジフテリア・破傷風・百日咳混合ワクチンの課題 - ジフテリア・破傷風・百日咳混合ワクチンの阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Diphtheria, Tetanus, and Pertussis Combined Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Diphtheria, Tetanus, and Pertussis Combined Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Diphtheria, Tetanus, and Pertussis Combined Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Diphtheria, Tetanus, and Pertussis Combined Vaccine include Sanofi Pasteur, GSK, Mitsubishi Tanabe Pharma, KM Biologics, Wuhan Institute of Biological Products, Walvax Biotechnology, Chengdu Institute of Biological Products and Minhai Biotechnology, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Diphtheria, Tetanus, and Pertussis Combined Vaccine manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Diphtheria, Tetanus, and Pertussis Combined Vaccine market. Further, it explains the major drivers and regional dynamics of the global Diphtheria, Tetanus, and Pertussis Combined Vaccine market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Sanofi Pasteur
GSK
Mitsubishi Tanabe Pharma
KM Biologics
Wuhan Institute of Biological Products
Walvax Biotechnology
Chengdu Institute of Biological Products
Minhai Biotechnology
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on sales, price, and value for the period 2017-2028.
Diphtheria, Tetanus, and Pertussis Combined Vaccine Segment by Type
Inactivated Vaccine
Other
Diphtheria, Tetanus, and Pertussis Combined Vaccine Segment by Application
12 Months Below
12 Months Above
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Diphtheria, Tetanus, and Pertussis Combined Vaccine market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Diphtheria, Tetanus, and Pertussis Combined Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Diphtheria, Tetanus, and Pertussis Combined Vaccine, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Diphtheria, Tetanus, and Pertussis Combined Vaccine, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Diphtheria, Tetanus, and Pertussis Combined Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Diphtheria, Tetanus, and Pertussis Combined Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Diphtheria, Tetanus, and Pertussis Combined Vaccine sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Sanofi Pasteur, GSK, Mitsubishi Tanabe Pharma, KM Biologics, Wuhan Institute of Biological Products, Walvax Biotechnology, Chengdu Institute of Biological Products and Minhai Biotechnology, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Diphtheria, Tetanus, and Pertussis Combined Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Diphtheria, Tetanus, and Pertussis Combined Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Diphtheria, Tetanus, and Pertussis Combined Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Diphtheria, Tetanus, and Pertussis Combined Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Inactivated Vaccine
1.2.3 Other
1.3 Market by Application
1.3.1 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 12 Months Below
1.3.3 12 Months Above
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Estimates and Forecasts 2017-2028
2.2 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue Estimates and Forecasts 2017-2028
2.3 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Region
2.4.1 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Region (2017-2022)
2.4.2 Global Sales Diphtheria, Tetanus, and Pertussis Combined Vaccine by Region (2023-2028)
2.5 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Region
2.5.1 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Region (2017-2022)
2.5.2 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Manufacturers
3.1.1 Global Top Diphtheria, Tetanus, and Pertussis Combined Vaccine Manufacturers by Sales (2017-2022)
3.1.2 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Diphtheria, Tetanus, and Pertussis Combined Vaccine in 2021
3.2 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Manufacturers
3.2.1 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Manufacturers (2017-2022)
3.2.2 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue in 2021
3.3 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Type
4.1.1 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Historical Sales by Type (2017-2022)
4.1.2 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Forecasted Sales by Type (2023-2028)
4.1.3 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Market Share by Type (2017-2028)
4.2 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Type
4.2.1 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Historical Revenue by Type (2017-2022)
4.2.2 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Forecasted Revenue by Type (2023-2028)
4.2.3 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue Market Share by Type (2017-2028)
4.3 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Price by Type
4.3.1 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Price by Type (2017-2022)
4.3.2 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Application
5.1.1 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Historical Sales by Application (2017-2022)
5.1.2 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Forecasted Sales by Application (2023-2028)
5.1.3 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Market Share by Application (2017-2028)
5.2 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Application
5.2.1 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Historical Revenue by Application (2017-2022)
5.2.2 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Forecasted Revenue by Application (2023-2028)
5.2.3 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue Market Share by Application (2017-2028)
5.3 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Price by Application
5.3.1 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Price by Application (2017-2022)
5.3.2 Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Price Forecast by Application (2023-2028)
6 North America
6.1 North America Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Size by Type
6.1.1 North America Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Type (2017-2028)
6.1.2 North America Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Type (2017-2028)
6.2 North America Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Size by Application
6.2.1 North America Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Application (2017-2028)
6.2.2 North America Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Application (2017-2028)
6.3 North America Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Size by Country
6.3.1 North America Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Country (2017-2028)
6.3.2 North America Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Size by Type
7.1.1 Europe Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Type (2017-2028)
7.1.2 Europe Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Type (2017-2028)
7.2 Europe Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Size by Application
7.2.1 Europe Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Application (2017-2028)
7.2.2 Europe Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Application (2017-2028)
7.3 Europe Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Size by Country
7.3.1 Europe Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Country (2017-2028)
7.3.2 Europe Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Size by Type
8.1.1 Asia Pacific Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Type (2017-2028)
8.1.2 Asia Pacific Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Type (2017-2028)
8.2 Asia Pacific Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Size by Application
8.2.1 Asia Pacific Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Application (2017-2028)
8.2.2 Asia Pacific Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Application (2017-2028)
8.3 Asia Pacific Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Size by Region
8.3.1 Asia Pacific Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Region (2017-2028)
8.3.2 Asia Pacific Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Size by Type
9.1.1 Latin America Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Type (2017-2028)
9.1.2 Latin America Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Type (2017-2028)
9.2 Latin America Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Size by Application
9.2.1 Latin America Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Application (2017-2028)
9.2.2 Latin America Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Application (2017-2028)
9.3 Latin America Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Size by Country
9.3.1 Latin America Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Country (2017-2028)
9.3.2 Latin America Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Size by Type
10.1.1 Middle East and Africa Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Type (2017-2028)
10.1.2 Middle East and Africa Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Type (2017-2028)
10.2 Middle East and Africa Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Size by Application
10.2.1 Middle East and Africa Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Application (2017-2028)
10.2.2 Middle East and Africa Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Application (2017-2028)
10.3 Middle East and Africa Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Size by Country
10.3.1 Middle East and Africa Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Country (2017-2028)
10.3.2 Middle East and Africa Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Sanofi Pasteur
11.1.1 Sanofi Pasteur Corporation Information
11.1.2 Sanofi Pasteur Overview
11.1.3 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis Combined Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Sanofi Pasteur Recent Developments
11.2 GSK
11.2.1 GSK Corporation Information
11.2.2 GSK Overview
11.2.3 GSK Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 GSK Diphtheria, Tetanus, and Pertussis Combined Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 GSK Recent Developments
11.3 Mitsubishi Tanabe Pharma
11.3.1 Mitsubishi Tanabe Pharma Corporation Information
11.3.2 Mitsubishi Tanabe Pharma Overview
11.3.3 Mitsubishi Tanabe Pharma Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Mitsubishi Tanabe Pharma Diphtheria, Tetanus, and Pertussis Combined Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Mitsubishi Tanabe Pharma Recent Developments
11.4 KM Biologics
11.4.1 KM Biologics Corporation Information
11.4.2 KM Biologics Overview
11.4.3 KM Biologics Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 KM Biologics Diphtheria, Tetanus, and Pertussis Combined Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 KM Biologics Recent Developments
11.5 Wuhan Institute of Biological Products
11.5.1 Wuhan Institute of Biological Products Corporation Information
11.5.2 Wuhan Institute of Biological Products Overview
11.5.3 Wuhan Institute of Biological Products Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Wuhan Institute of Biological Products Diphtheria, Tetanus, and Pertussis Combined Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Wuhan Institute of Biological Products Recent Developments
11.6 Walvax Biotechnology
11.6.1 Walvax Biotechnology Corporation Information
11.6.2 Walvax Biotechnology Overview
11.6.3 Walvax Biotechnology Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Walvax Biotechnology Diphtheria, Tetanus, and Pertussis Combined Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Walvax Biotechnology Recent Developments
11.7 Chengdu Institute of Biological Products
11.7.1 Chengdu Institute of Biological Products Corporation Information
11.7.2 Chengdu Institute of Biological Products Overview
11.7.3 Chengdu Institute of Biological Products Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Chengdu Institute of Biological Products Diphtheria, Tetanus, and Pertussis Combined Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Chengdu Institute of Biological Products Recent Developments
11.8 Minhai Biotechnology
11.8.1 Minhai Biotechnology Corporation Information
11.8.2 Minhai Biotechnology Overview
11.8.3 Minhai Biotechnology Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Minhai Biotechnology Diphtheria, Tetanus, and Pertussis Combined Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Minhai Biotechnology Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Diphtheria, Tetanus, and Pertussis Combined Vaccine Industry Chain Analysis
12.2 Diphtheria, Tetanus, and Pertussis Combined Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Diphtheria, Tetanus, and Pertussis Combined Vaccine Production Mode & Process
12.4 Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales and Marketing
12.4.1 Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Channels
12.4.2 Diphtheria, Tetanus, and Pertussis Combined Vaccine Distributors
12.5 Diphtheria, Tetanus, and Pertussis Combined Vaccine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Diphtheria, Tetanus, and Pertussis Combined Vaccine Industry Trends
13.2 Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Drivers
13.3 Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Challenges
13.4 Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Restraints
14 Key Findings in The Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
Table 1. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Inactivated Vaccine
Table 3. Major Manufacturers of Other
Table 4. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 5. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Region (2017-2022) & (Million Doses)
Table 7. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Market Share by Region (2017-2022)
Table 8. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Region (2023-2028) & (Million Doses)
Table 9. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Market Share by Region (2023-2028)
Table 10. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 11. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue Market Share by Region (2017-2022)
Table 12. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Region (2023-2028) & (US$ Million)
Table 13. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue Market Share by Region (2023-2028)
Table 14. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Manufacturers (2017-2022) & (Million Doses)
Table 15. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Share by Manufacturers (2017-2022)
Table 16. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 17. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue Share by Manufacturers (2017-2022)
Table 18. Diphtheria, Tetanus, and Pertussis Combined Vaccine Price by Manufacturers (2017-2022) &(USD/Dose)
Table 19. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 20. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Diphtheria, Tetanus, and Pertussis Combined Vaccine as of 2021)
Table 21. Diphtheria, Tetanus, and Pertussis Combined Vaccine Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Diphtheria, Tetanus, and Pertussis Combined Vaccine Product Offered
Table 23. Date of Manufacturers Enter into Diphtheria, Tetanus, and Pertussis Combined Vaccine Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Type (2017-2022) & (Million Doses)
Table 26. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Type (2023-2028) & (Million Doses)
Table 27. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Share by Type (2017-2022)
Table 28. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Share by Type (2023-2028)
Table 29. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 30. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 31. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue Share by Type (2017-2022)
Table 32. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue Share by Type (2023-2028)
Table 33. Diphtheria, Tetanus, and Pertussis Combined Vaccine Price by Type (2017-2022) & (USD/Dose)
Table 34. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Price Forecast by Type (2023-2028) & (USD/Dose)
Table 35. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Application (2017-2022) & (Million Doses)
Table 36. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Application (2023-2028) & (Million Doses)
Table 37. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Share by Application (2017-2022)
Table 38. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Share by Application (2023-2028)
Table 39. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 40. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 41. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue Share by Application (2017-2022)
Table 42. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue Share by Application (2023-2028)
Table 43. Diphtheria, Tetanus, and Pertussis Combined Vaccine Price by Application (2017-2022) & (USD/Dose)
Table 44. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Price Forecast by Application (2023-2028) & (USD/Dose)
Table 45. North America Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Type (2017-2022) & (Million Doses)
Table 46. North America Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Type (2023-2028) & (Million Doses)
Table 47. North America Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 48. North America Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 49. North America Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Application (2017-2022) & (Million Doses)
Table 50. North America Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Application (2023-2028) & (Million Doses)
Table 51. North America Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 52. North America Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 53. North America Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Country (2017-2022) & (Million Doses)
Table 54. North America Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Country (2023-2028) & (Million Doses)
Table 55. North America Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 56. North America Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 57. Europe Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Type (2017-2022) & (Million Doses)
Table 58. Europe Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Type (2023-2028) & (Million Doses)
Table 59. Europe Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 60. Europe Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 61. Europe Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Application (2017-2022) & (Million Doses)
Table 62. Europe Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Application (2023-2028) & (Million Doses)
Table 63. Europe Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 64. Europe Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 65. Europe Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Country (2017-2022) & (Million Doses)
Table 66. Europe Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Country (2023-2028) & (Million Doses)
Table 67. Europe Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 68. Europe Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 69. Asia Pacific Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Type (2017-2022) & (Million Doses)
Table 70. Asia Pacific Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Type (2023-2028) & (Million Doses)
Table 71. Asia Pacific Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 72. Asia Pacific Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 73. Asia Pacific Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Application (2017-2022) & (Million Doses)
Table 74. Asia Pacific Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Application (2023-2028) & (Million Doses)
Table 75. Asia Pacific Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 76. Asia Pacific Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 77. Asia Pacific Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Region (2017-2022) & (Million Doses)
Table 78. Asia Pacific Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Region (2023-2028) & (Million Doses)
Table 79. Asia Pacific Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 80. Asia Pacific Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Region (2023-2028) & (US$ Million)
Table 81. Latin America Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Type (2017-2022) & (Million Doses)
Table 82. Latin America Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Type (2023-2028) & (Million Doses)
Table 83. Latin America Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 84. Latin America Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 85. Latin America Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Application (2017-2022) & (Million Doses)
Table 86. Latin America Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Application (2023-2028) & (Million Doses)
Table 87. Latin America Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 88. Latin America Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 89. Latin America Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Country (2017-2022) & (Million Doses)
Table 90. Latin America Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Country (2023-2028) & (Million Doses)
Table 91. Latin America Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 92. Latin America Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 93. Middle East and Africa Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Type (2017-2022) & (Million Doses)
Table 94. Middle East and Africa Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Type (2023-2028) & (Million Doses)
Table 95. Middle East and Africa Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 96. Middle East and Africa Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 97. Middle East and Africa Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Application (2017-2022) & (Million Doses)
Table 98. Middle East and Africa Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Application (2023-2028) & (Million Doses)
Table 99. Middle East and Africa Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 100. Middle East and Africa Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 101. Middle East and Africa Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Country (2017-2022) & (Million Doses)
Table 102. Middle East and Africa Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales by Country (2023-2028) & (Million Doses)
Table 103. Middle East and Africa Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 104. Middle East and Africa Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 105. Sanofi Pasteur Corporation Information
Table 106. Sanofi Pasteur Description and Major Businesses
Table 107. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales (Million Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 108. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis Combined Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 109. Sanofi Pasteur Recent Developments
Table 110. GSK Corporation Information
Table 111. GSK Description and Major Businesses
Table 112. GSK Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales (Million Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 113. GSK Diphtheria, Tetanus, and Pertussis Combined Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 114. GSK Recent Developments
Table 115. Mitsubishi Tanabe Pharma Corporation Information
Table 116. Mitsubishi Tanabe Pharma Description and Major Businesses
Table 117. Mitsubishi Tanabe Pharma Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales (Million Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 118. Mitsubishi Tanabe Pharma Diphtheria, Tetanus, and Pertussis Combined Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 119. Mitsubishi Tanabe Pharma Recent Developments
Table 120. KM Biologics Corporation Information
Table 121. KM Biologics Description and Major Businesses
Table 122. KM Biologics Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales (Million Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 123. KM Biologics Diphtheria, Tetanus, and Pertussis Combined Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 124. KM Biologics Recent Developments
Table 125. Wuhan Institute of Biological Products Corporation Information
Table 126. Wuhan Institute of Biological Products Description and Major Businesses
Table 127. Wuhan Institute of Biological Products Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales (Million Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 128. Wuhan Institute of Biological Products Diphtheria, Tetanus, and Pertussis Combined Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 129. Wuhan Institute of Biological Products Recent Developments
Table 130. Walvax Biotechnology Corporation Information
Table 131. Walvax Biotechnology Description and Major Businesses
Table 132. Walvax Biotechnology Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales (Million Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 133. Walvax Biotechnology Diphtheria, Tetanus, and Pertussis Combined Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 134. Walvax Biotechnology Recent Developments
Table 135. Chengdu Institute of Biological Products Corporation Information
Table 136. Chengdu Institute of Biological Products Description and Major Businesses
Table 137. Chengdu Institute of Biological Products Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales (Million Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 138. Chengdu Institute of Biological Products Diphtheria, Tetanus, and Pertussis Combined Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 139. Chengdu Institute of Biological Products Recent Developments
Table 140. Minhai Biotechnology Corporation Information
Table 141. Minhai Biotechnology Description and Major Businesses
Table 142. Minhai Biotechnology Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales (Million Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 143. Minhai Biotechnology Diphtheria, Tetanus, and Pertussis Combined Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 144. Minhai Biotechnology Recent Developments
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. Diphtheria, Tetanus, and Pertussis Combined Vaccine Distributors List
Table 148. Diphtheria, Tetanus, and Pertussis Combined Vaccine Customers List
Table 149. Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Trends
Table 150. Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Drivers
Table 151. Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Challenges
Table 152. Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Diphtheria, Tetanus, and Pertussis Combined Vaccine Product Picture
Figure 2. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Share by Type in 2021 & 2028
Figure 3. Inactivated Vaccine Product Picture
Figure 4. Other Product Picture
Figure 5. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Share by Application in 2021 & 2028
Figure 6. 12 Months Below
Figure 7. 12 Months Above
Figure 8. Diphtheria, Tetanus, and Pertussis Combined Vaccine Report Years Considered
Figure 9. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales 2017-2028 (Million Doses)
Figure 10. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue 2017-2028 (US$ Million)
Figure 12. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 13. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Market Share by Region (2017-2022)
Figure 14. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Market Share by Region (2023-2028)
Figure 15. North America Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales YoY (2017-2028) & (Million Doses)
Figure 16. North America Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 17. Europe Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales YoY (2017-2028) & (Million Doses)
Figure 18. Europe Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 19. Asia-Pacific Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales YoY (2017-2028) & (Million Doses)
Figure 20. Asia-Pacific Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Latin America Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales YoY (2017-2028) & (Million Doses)
Figure 22. Latin America Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Middle East & Africa Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales YoY (2017-2028) & (Million Doses)
Figure 24. Middle East & Africa Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 25. The Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 26. The Top 5 and 10 Largest Manufacturers of Diphtheria, Tetanus, and Pertussis Combined Vaccine in the World: Market Share by Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue in 2021
Figure 27. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 28. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Market Share by Type (2017-2028)
Figure 29. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue Market Share by Type (2017-2028)
Figure 30. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Market Share by Application (2017-2028)
Figure 31. Global Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue Market Share by Application (2017-2028)
Figure 32. North America Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Market Share by Type (2017-2028)
Figure 33. North America Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue Market Share by Type (2017-2028)
Figure 34. North America Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Market Share by Application (2017-2028)
Figure 35. North America Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue Market Share by Application (2017-2028)
Figure 36. North America Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Share by Country (2017-2028)
Figure 37. North America Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue Share by Country (2017-2028)
Figure 38. United States Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 39. Canada Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 40. Europe Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Market Share by Type (2017-2028)
Figure 41. Europe Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue Market Share by Type (2017-2028)
Figure 42. Europe Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Market Share by Application (2017-2028)
Figure 43. Europe Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue Market Share by Application (2017-2028)
Figure 44. Europe Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Share by Country (2017-2028)
Figure 45. Europe Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue Share by Country (2017-2028)
Figure 46. Germany Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 47. France Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 48. U.K. Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 49. Italy Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 50. Russia Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 51. Asia Pacific Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Market Share by Type (2017-2028)
Figure 52. Asia Pacific Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue Market Share by Type (2017-2028)
Figure 53. Asia Pacific Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Market Share by Application (2017-2028)
Figure 54. Asia Pacific Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue Market Share by Application (2017-2028)
Figure 55. Asia Pacific Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Share by Region (2017-2028)
Figure 56. Asia Pacific Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue Share by Region (2017-2028)
Figure 57. China Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 58. Japan Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 59. South Korea Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 60. India Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 61. Australia Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 62. China Taiwan Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 63. Indonesia Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 64. Thailand Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 65. Malaysia Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 66. Latin America Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Market Share by Type (2017-2028)
Figure 67. Latin America Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue Market Share by Type (2017-2028)
Figure 68. Latin America Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Market Share by Application (2017-2028)
Figure 69. Latin America Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue Market Share by Application (2017-2028)
Figure 70. Latin America Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Share by Country (2017-2028)
Figure 71. Latin America Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue Share by Country (2017-2028)
Figure 72. Mexico Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 73. Brazil Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 74. Argentina Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 75. Colombia Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 76. Middle East and Africa Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Market Share by Type (2017-2028)
Figure 77. Middle East and Africa Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue Market Share by Type (2017-2028)
Figure 78. Middle East and Africa Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Market Share by Application (2017-2028)
Figure 79. Middle East and Africa Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue Market Share by Application (2017-2028)
Figure 80. Middle East and Africa Diphtheria, Tetanus, and Pertussis Combined Vaccine Sales Share by Country (2017-2028)
Figure 81. Middle East and Africa Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue Share by Country (2017-2028)
Figure 82. Turkey Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 83. Saudi Arabia Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 84. UAE Diphtheria, Tetanus, and Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 85. Diphtheria, Tetanus, and Pertussis Combined Vaccine Value Chain
Figure 86. Diphtheria, Tetanus, and Pertussis Combined Vaccine Production Process
Figure 87. Channels of Distribution
Figure 88. Distributors Profiles
Figure 89. Bottom-up and Top-down Approaches for This Report
Figure 90. Data Triangulation
Figure 91. Key Executives Interviewed